Latest news and articles about novo nordisk from NEX English
A new weight loss medication from <strong>Lilly</strong> has received approval from the <strong>U.S. Food and Drug Administration</strong>, paving the way for strong competition with <strong>Novo Nordisk</strong>. This development comes at a time when interest in obesity treatments is surging in the United States.
Novo Nordisk has achieved the best obesity drug launch this year with its medication Wegovy, surpassing 600,000 prescriptions. This move comes as Eli Lilly intensifies competition by introducing new pills to attract patients.
Novo Nordisk announced a rise in its shares by up to 4% following a recommendation from the National Institute for Health and Care Excellence (NICE) in England to use Wegovy as a treatment for preventing heart attacks and strokes. This decision significantly expands patient access to this effective treatment within the English healthcare system.
Novo Nordisk has announced the launch of long-term subscriptions for Wegovy medications aimed at combating obesity, offering users savings of up to <strong>$1,200 annually</strong> on injections and <strong>$600 annually</strong> on pills. This initiative is part of the company's strategy to compete with Eli Lilly.